Evidence map›Paper›PMID 35119591›Full record

ArticleClinical and experimental medicine2023

Toll- like receptor 2 polymorphism and IL-6 profile in relation to disease progression in chronic HBV infection: a case control study in Egyptian patients.

Asmaa M Elbrolosy, Naglaa S Elabd, Gamalat A ElGedawy, Mai Abozeid, Mervat Abdelkreem, Belal Montaser, Emad M Eed, Moamena S Elhamouly

Open access · hybridAbstract read
In one paragraph

Article in Clinical and experimental medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Insights into the Correlation between Toll-Like Receptor 2 Polymorphism and HBV-Related Disease Progression and Occurrence of Hepatocellular Carcinoma: A Case-Control Study in Egyptian Patients.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Asmaa M ElbrolosyMedical Microbiology and Immunology Department, Faculty of Medicine, Menoufia University, Shebin El-Kom, 32511, Egypt.
Naglaa S ElabdTropical Medicine Department, Faculty of Medicine, Menoufia University, Shebin El-Kom, 32511, Egypt.
Gamalat A ElGedawyClinical Biochemistry and Molecular Diagnostics Department, National Liver Institute, Menoufia University, Shebin El-Kom, 32511, Egypt.
Mai AbozeidHepatology and Gastroenterology Department, National Liver Institute, Menoufia University, Shebin El-Kom, 32511, Egypt. dr.maiabozeid@gmail.com.ORCID http://orcid.org/0000-0003-1808-7928
Mervat AbdelkreemHepatology and Gastroenterology Department, National Liver Institute, Menoufia University, Shebin El-Kom, 32511, Egypt.
Belal MontaserClinical Pathology Department, Faculty of Medicine, Menoufia University, Shebin El-Kom, 32511, Egypt.
Emad M EedMedical Microbiology and Immunology Department, Faculty of Medicine, Menoufia University, Shebin El-Kom, 32511, Egypt.
Moamena S ElhamoulyTropical Medicine Department, Faculty of Medicine, Menoufia University, Shebin El-Kom, 32511, Egypt.
Menoufia University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic hepatitis B (CHB) has a wide range of outcomes depending on host immune responses mainly Toll-like receptors (TLRs) signaling and released cytokines. Toll-like receptor 2 (TLR2) single nucleotide polymorphisms (SNPs) and interleukin 6 (IL-6) may influence the course of CHB. We aimed to elucidate the relation between TLR-2 polymorphism, IL-6 profile, and CHB progression. We analyzed TLR-2 polymorphism (SNP; rs3804099) in 185 CHB patients and 60 controls using TaqMan allelic discrimination assay. Serum IL-6 levels were assessed by ELISA. IL-6 levels were considerably higher in active CHB and cirrhotic patients compared with inactive carriers and controls (P < 0.001). IL-6 showed positive correlation with ALT and advanced fibrosis in active CHB patients (r = 0.31, P = 0.02). A significant positive correlation was noticed between IL-6 and HBV DNA PCR in all CHB groups. TT genotype of rs3804099/TLR-2 was significantly more prevalent in inactive carriers compared to active hepatitis patients (P = 0.04, OR = 0.39 and 95% CI: 0.16-0.95). Both heterozygous CT and mutant TT genotypes were significantly more frequent among inactive carriers compared to cirrhotic patients (P = 0.01, OR = 0.33, 95% CI: 0.13-0.81 and P = 0.009, OR = 0.32, 95% CI: 0.13-0.77). TT genotype was significantly related to lower IL-6 levels in active hepatitis and cirrhotic groups (P = 0.005 and P = 0.001, respectively) showing that TLR mutations would be associated with milder hepatitis activity and lower possibility for disease progression. There may be a positive association between TLR2 rs3804099 polymorphism and hepatitis B activity. IL-6 is a good indicator of CHB disease progression.

Indexed as

Hepatitis B, ChronicInterleukin-6Case-Control StudiesDisease ProgressionEgyptHepatitis B virusHumansLiver CirrhosisPolymorphism, Single NucleotideToll-Like Receptor 2Interleukin-6Toll-Like Receptor 2HBVIL-6SNPsTLR-2

Identifiers

PMID35119591
PMCPMC9939497
OpenAlexW4210616201

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.